Related Experiment Video
Updated: Jan 8, 2026
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Overcoming BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia by Targeting PKCβ
Billy Michael Chelliah Jebaraj1, Stephan Stilgenbauer1
1Division of CLL, Department of Internal Medicine III, Ulm University, Ulm, Germany.
Abstract:
Resistance of chronic lymphocytic leukemia to BTK inhibitors poses a major clinical challenge; however, there is potential to overcome this obstacle by targeting the downstream protein kinase PKCβ using the novel inhibitor MS-553. By inhibiting PKCβ, MS-553 blocks B-cell receptor signaling and WNT/β-catenin and NF-κB functions, thereby inducing apoptosis in BTK inhibitor-resistant cells. See related article by Gordon et al., p. 85.
Insights
Novel inhibitor MS-553 targets protein kinase PKCβ to overcome resistance in chronic lymphocytic leukemia (CLL) to BTK inhibitors. This approach induces apoptosis in resistant cells by blocking key signaling pathways.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Resistance to Bruton's tyrosine kinase (BTK) inhibitors is a significant clinical challenge in treating chronic lymphocytic leukemia (CLL).
- Identifying alternative therapeutic targets is crucial for managing refractory CLL cases.
Purpose of the Study:
- To investigate the efficacy of a novel protein kinase C beta (PKCβ) inhibitor, MS-553, in overcoming BTK inhibitor resistance in CLL.
- To elucidate the molecular mechanisms by which MS-553 exerts its anti-leukemic effects.
Main Methods:
- Utilized MS-553, a novel PKCβ inhibitor.
- Assessed the impact of MS-553 on B-cell receptor signaling, WNT/β-catenin, and NF-κB pathways.
- Evaluated apoptosis induction in BTK inhibitor-resistant CLL cells.
Main Results:
- MS-553 effectively inhibits PKCβ activity.
- Inhibition of PKCβ by MS-553 disrupts B-cell receptor signaling, WNT/β-catenin, and NF-κB pathways.
- MS-553 demonstrates potent apoptosis-inducing activity in CLL cells resistant to BTK inhibitors.
Conclusions:
- MS-553 represents a promising therapeutic strategy for overcoming BTK inhibitor resistance in chronic lymphocytic leukemia.
- Targeting PKCβ offers a viable approach to restore sensitivity to treatment in refractory CLL.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:34Inhibition of Cdk Activity
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...